Offered by: Nemours Children's
Locations: Delaware Valley and Jacksonville, Orlando and Pensacola in Florida
A Phase 2 Multicenter Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
To look at the survival rate when a drug called dasatinib is added to standard chemotherapy.
Age > 1 year and < 18
Length of study is approximately 7 years. Tests and procedures to be done include: Review of medical history; Complete physical exam; Assessment of performance status; Chest X-ray; ECG; ECHO); Collection of blood and urine samples; Spinal tap; DXA; minimal residual disease test; pregnancy test.
Trial Name: A Phase 2 Multicenter Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
COG#: AALL1122
(800) 354-5690 Email UsLearn more about clinical trials and get answers to questions you might have.
Go to FAQs View All Clinical TrialsNemours has a number of service regions. Selecting your region will help us show you the right contact information and the most relevant content for you.